9FU2 | pdb_00009fu2

Smooth Muscle Myosin II in complex with MT-228

  • Classification: MOTOR PROTEIN
  • Organism(s): Homo sapiens
  • Expression System: Spodoptera frugiperda
  • Mutation(s): No 

  • Deposited: 2024-06-26 Released: 2025-07-09 
  • Deposition Author(s): Kikuti, C.M., Houdusse, A.
  • Funding Organization(s): Agence Nationale de la Recherche (ANR), National Institutes of Health/National Institute on Drug Abuse (NIH/NIDA), National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS)

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.58 Å
  • R-Value Free: 
    0.250 (Depositor), 0.242 (DCC) 
  • R-Value Work: 
    0.229 (Depositor), 0.222 (DCC) 
  • R-Value Observed: 
    0.230 (Depositor) 

Starting Model: in silico
View more details

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.2 of the entry. See complete history


Literature

Development of clinically viable non-muscle myosin II small molecule inhibitors.

Radnai, L.Young, E.J.Kikuti, C.Toth, K.Zhou, M.Hafenbreidel, M.Stremel, R.F.Lin, L.Pasetto, P.Jin, X.Patel, A.Conlon, M.Briggs, S.B.Heidsieck, L.Sweeney, H.L.Sellers, J.Krieger-Burke, T.Martin, W.H.Sisco, J.Young, S.Pearson, P.Rumbaugh, G.Araldi, G.L.Duddy, S.K.Cameron, M.D.Surman, M.Houdusse, A.Griffin, P.R.Kamenecka, T.M.Miller, C.A.

(2025) Cell 188: 4604-4621.e15

  • DOI: https://doi.org/10.1016/j.cell.2025.06.006
  • Primary Citation of Related Structures:  
    9FU2

  • PubMed Abstract: 

    Non-muscle myosin II (NMII), a molecular motor that regulates critical processes such as cytokinesis and neuronal plasticity, has substantial therapeutic potential. However, translating this potential to in vivo use has been hampered by a lack of selective tools. The most prototypical non-selective inhibitor inactivates both NMII and cardiac muscle myosin II (CMII), a key regulator of heart function. Using rational drug design, we developed a series of NMII inhibitors that markedly improve tolerability by selectively targeting NMII over CMII, including MT-228 and clinical candidate MT-110. MT-228 and MT-110 have excellent properties, including high brain penetration and efficacy in preclinical models of methamphetamine use disorder (MUD), which has no current FDA-approved therapies. The structure of MT-228 bound to myosin II provides insight into its selectivity for NMII over CMII. The broad therapeutic windows of these NMII inhibitors provide valuable tools for the scientific community and a promising clinical candidate for the treatment of MUD.


  • Organizational Affiliation
    • Department of Molecular Medicine, The Scripps Research Institute and The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL 33458, USA; Department of Neuroscience, The Scripps Research Institute and The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL 33458, USA.

Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Myosin-111,972Homo sapiensMutation(s): 0 
Gene Names: MYH11KIAA0866
UniProt & NIH Common Fund Data Resources
Find proteins for P35749 (Homo sapiens)
Explore P35749 
Go to UniProtKB:  P35749
PHAROS:  P35749
GTEx:  ENSG00000133392 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP35749
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Ligands 7 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
ADP
Query on ADP

Download Ideal Coordinates CCD File 
B [auth A]ADENOSINE-5'-DIPHOSPHATE
C10 H15 N5 O10 P2
XTWYTFMLZFPYCI-KQYNXXCUSA-N
A1IGE (Subject of Investigation/LOI)
Query on A1IGE

Download Ideal Coordinates CCD File 
I [auth A](3~{a}~{S})-1-(2-methoxypyridin-4-yl)-6,7-dimethyl-3~{a}-oxidanyl-2,3-dihydropyrrolo[2,3-b]quinolin-4-one
C19 H19 N3 O3
DUDYNUXUMAKUPK-LJQANCHMSA-N
VO4
Query on VO4

Download Ideal Coordinates CCD File 
C [auth A]VANADATE ION
O4 V
LSGOVYNHVSXFFJ-UHFFFAOYSA-N
DMS
Query on DMS

Download Ideal Coordinates CCD File 
E [auth A],
K [auth A],
N [auth A]
DIMETHYL SULFOXIDE
C2 H6 O S
IAZDPXIOMUYVGZ-UHFFFAOYSA-N
EDO
Query on EDO

Download Ideal Coordinates CCD File 
F [auth A]
G [auth A]
H [auth A]
J [auth A]
L [auth A]
F [auth A],
G [auth A],
H [auth A],
J [auth A],
L [auth A],
M [auth A]
1,2-ETHANEDIOL
C2 H6 O2
LYCAIKOWRPUZTN-UHFFFAOYSA-N
CL
Query on CL

Download Ideal Coordinates CCD File 
O [auth A]CHLORIDE ION
Cl
VEXZGXHMUGYJMC-UHFFFAOYSA-M
MG
Query on MG

Download Ideal Coordinates CCD File 
D [auth A]MAGNESIUM ION
Mg
JLVVSXFLKOJNIY-UHFFFAOYSA-N
Modified Residues  1 Unique
IDChains TypeFormula2D DiagramParent
MLY
Query on MLY
A
L-PEPTIDE LINKINGC8 H18 N2 O2LYS
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.58 Å
  • R-Value Free:  0.250 (Depositor), 0.242 (DCC) 
  • R-Value Work:  0.229 (Depositor), 0.222 (DCC) 
  • R-Value Observed: 0.230 (Depositor) 
Space Group: P 31
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 83.106α = 90
b = 83.106β = 90
c = 132.251γ = 120
Software Package:
Software NamePurpose
BUSTERrefinement
XDSdata reduction
Aimlessdata scaling
MOLREPphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Agence Nationale de la Recherche (ANR)FranceANR-21-Ce11-0022-01
National Institutes of Health/National Institute on Drug Abuse (NIH/NIDA)United StatesR01DA049544
National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS)United StatesR33NS119714
National Institutes of Health/National Institute on Drug Abuse (NIH/NIDA)United StatesUH3NS096833

Revision History  (Full details and data files)

  • Version 1.0: 2025-07-09
    Type: Initial release
  • Version 1.1: 2025-07-16
    Changes: Database references
  • Version 1.2: 2025-09-03
    Changes: Database references